Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer.
Drisko JA, Chapman J, Hunter VJ. Drisko JA, et al. Among authors: hunter vj. J Am Coll Nutr. 2003 Apr;22(2):118-23. doi: 10.1080/07315724.2003.10719284. J Am Coll Nutr. 2003. PMID: 12672707
CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer.
Hunter VJ, Weinberg JB, Haney AF, Soper JT, Lavin P, Metsch L, Knapp RC, Bast RC Jr. Hunter VJ, et al. Gynecol Oncol. 1990 Feb;36(2):161-5. doi: 10.1016/0090-8258(90)90165-h. Gynecol Oncol. 1990. PMID: 2404835
Reduction of tumor necrosis factor-alpha bioactivity by a human ovarian epithelial cancer cell line in vitro.
Sancho-Tello M, Marcinkiewicz JL, Justice WM, Kimler BF, Terranova PF, Hunter VJ. Sancho-Tello M, et al. Among authors: hunter vj. Am J Obstet Gynecol. 1995 Nov;173(5):1470-7. doi: 10.1016/0002-9378(95)90635-5. Am J Obstet Gynecol. 1995. PMID: 7503187
Epithelial ovarian tumors of low malignant potential.
Massad LS Jr, Hunter VJ, Szpak CA, Clarke-Pearson DL, Creasman WT. Massad LS Jr, et al. Among authors: hunter vj. Obstet Gynecol. 1991 Dec;78(6):1027-32. Obstet Gynecol. 1991. PMID: 1945202 Review.
The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.
Hunter VJ, Daly L, Helms M, Soper JT, Berchuck A, Clarke-Pearson DL, Bast RC Jr. Hunter VJ, et al. Am J Obstet Gynecol. 1990 Oct;163(4 Pt 1):1164-7. doi: 10.1016/0002-9378(90)90680-6. Am J Obstet Gynecol. 1990. PMID: 2171337
The use of antioxidant therapies during chemotherapy.
Drisko JA, Chapman J, Hunter VJ. Drisko JA, et al. Among authors: hunter vj. Gynecol Oncol. 2003 Mar;88(3):434-9. doi: 10.1016/s0090-8258(02)00067-7. Gynecol Oncol. 2003. PMID: 12648599 Review.
Peritoneal papillary serous carcinoma in a woman with a history of utero DES exposure.
Seoud MA, Tawfik O, Hunter V. Seoud MA, et al. Gynecol Oncol. 1993 Sep;50(3):371-3. doi: 10.1006/gyno.1993.1228. Gynecol Oncol. 1993. PMID: 8406204
Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).
Rothenberg ML, Liu PY, Wilczynski S, Hannigan EV, Weiner SA, Weiss GR, Hunter VJ, Chapman JA, Tiersten A, Kohler PC, Alberts DS. Rothenberg ML, et al. Among authors: hunter vj. Gynecol Oncol. 2001 Aug;82(2):317-22. doi: 10.1006/gyno.2001.6274. Gynecol Oncol. 2001. PMID: 11531286 Clinical Trial.
Tumor necrosis factor-alpha alters steroidogenesis and stimulates proliferation of human ovarian granulosal cells in vitro.
Yan Z, Hunter V, Weed J, Hutchison S, Lyles R, Terranova P. Yan Z, et al. Fertil Steril. 1993 Feb;59(2):332-8. doi: 10.1016/s0015-0282(16)55676-3. Fertil Steril. 1993. PMID: 8425627
Short gracilis myocutaneous flaps for vulvovaginal reconstruction after radical pelvic surgery.
Soper JT, Larson D, Hunter VJ, Berchuck A, Clarke-Pearson DL. Soper JT, et al. Among authors: hunter vj. Obstet Gynecol. 1989 Nov;74(5):823-7. Obstet Gynecol. 1989. PMID: 2812660
13 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback